Tumor vaccines--application to childhood cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Klinische Pädiatrie

• Publication date

  1999-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/S-2008-1043811PMID 10472573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic Vaccine

  1998cited by this paper
• Cancer vaccines

  1998cited by this paper
• Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

  1998cited by this paper
• Patterns for RANTES Secretion and Intercellular Adhesion Molecule 1 Expression Mediate Transepithelial T Cell Traffic Based on Analyses In Vitro and In Vivo

  1998cited by this paper
• Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment

  1998cited by this paper
• Dendritic cell-based immunotherapy of prostate cancer.

  1998cited by this paper
• [Prognosis of children with acute myelocytic leukemia after first relapse].

  1998cited by this paper
• Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

  1998cited by this paper
• Induction of a CD3+/CD56+ lymphocyte population following gene therapy with transgenic IL-2 secreting fibroblasts in a child with peripheral neuroectodermal malignancy.

  1998cited by this paper
• T cell–tumor cell: a fatal interaction?

  1998cited by this paper
• Gene delivery to human B-precursor acute lymphoblastic leukemia cells.

  1998cited by this paper
• Interleukin-2 Gene-Modified Allogeneic Tumor Cells for Treatment of Relapsed Neuroblastoma

  1998cited by this paper
• Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

  1998cited by this paper
• CD40 ligand induces an antileukemia immune response in vivo.

  1997cited by this paper
• A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells.

  1997cited by this paper
• Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

  1997cited by this paper
• Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction.

  1997cited by this paper
• Follow‐up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

  1997cited by this paper
• Does megatherapy contribute to survival in metastatic neuroblastoma?

  1997cited by this paper
• Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

  1997cited by this paper
• Viral vectors for gene therapy of hematopoietic cells.

  1997cited by this paper
• Antitumor Responses Induced by Transgenic Expression of CD40 Ligand

  1997cited by this paper
• Replication-defective herpes simplex virus vectors for gene transfer in vivo.

  1996cited by this paper
• Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand‐dependent pathway

  1996cited by this paper
• Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood — follow up after 9 years

  1996cited by this paper
• In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter.

  1996cited by this paper
• Identification of the genes encoding cancer antigens: implications for cancer immunotherapy.

  1996cited by this paper
• Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

  1996cited by this paper
• Peptide‐pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA‐A*0201‐binding peptides from the Melan‐A/MART‐1 self antigen

  1996cited by this paper
• Human tumor antigens recognized by T lymphocytes

  1996cited by this paper
• Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

  1996cited by this paper
• Combined chemokine and cytokine gene transfer enhances antitumor immunity

  1996cited by this paper
• Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.

  1996cited by this paper
• Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

  1996cited by this paper
• Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes.

  1996cited by this paper
• Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas.

  1996cited by this paper
• Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML.

  1996cited by this paper
• Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1).

  1996cited by this paper
• High-Efficiency Transduction of Freshly Isolated Human Tumor Cells Using Adenoviral Interleukin-2 Vectors

  1996cited by this paper
• Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes

  1995cited by this paper
• A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.

  1995cited by this paper
• Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.

  1995cited by this paper
• Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

  1995cited by this paper
• Treatment of Patients with Acute Myelogenous Leukemia: Review of Clinical Trials of the Past Decade

  1995cited by this paper
• Role of B7-1 in mediating an immune response to myeloid leukemia cells.

  1995cited by this paper
• Molecular cloning and functional characterization of human lymphotactin.

  1995cited by this paper
• Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis.

  1995cited by this paper
• Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells

  1994cited by this paper
• Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones.

  1994cited by this paper
• In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.

  1994cited by this paper
• Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

  1994cited by this paper
• Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation.

  1994cited by this paper
• Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

  1994cited by this paper
• Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

  1994cited by this paper
• Activation of human dendritic cells through CD40 cross-linking

  1994cited by this paper
• Recombinant CD40 ligand exerts potent biologic effects on T cells.

  1994cited by this paper
• Role of the CD40‐CD40 ligand interaction in CD4+ T cell contact‐dependent activation of monocyte interleukin‐1 synthesis

  1994cited by this paper
• CD40 preferentially costimulates activation of CD4+ T lymphocytes.

  1994cited by this paper
• Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.

  1994cited by this paper
• Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

  1994cited by this paper
• Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2.

  1994cited by this paper
• Lymphotactin: a cytokine that represents a new class of chemokine.

  1994cited by this paper
• Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital.

  1993cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40

  1993cited by this paper
• Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.

  1993cited by this paper
• T-cell immunity to the joining region of p210BCR-ABL protein.

  1992cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.

  1992cited by this paper
• Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted

  1992cited by this paper
• Retroviral vectors.

  1992cited by this paper
• Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.

  1992cited by this paper
• Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

  1991cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• Interleukin 7 induces CD4+ T cell-dependent tumor rejection

  1991cited by this paper
• Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.

  1991cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.

  1990cited by this paper
• Graft-versus-leukemia reactions after bone marrow transplantation.

  1990cited by this paper
• Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.

  1990cited by this paper
• In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation.

  1989cited by this paper
• A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.

  1989cited by this paper
• Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.

  1989cited by this paper
• Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.

  1989cited by this paper
• Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.

  1989cited by this paper
• In vitro induction of lymphokine-activated killer (LAK) activity in patients with neuroblastoma.

  1989cited by this paper
• Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4

  1985cited by this paper
• Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small‐cell carcinoma of the lung: A Southwest Oncology group study

  1982cited by this paper
• High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.

  1982cited by this paper
• Do infants with stage IV-S neuroblastoma need treatment?

  1981cited by this paper
• Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

  1979cited by this paper

• Cancer vaccines: emphasis on pediatric cancers.

  2010cites this paper
• Herstellung einer Leukämievakzine durch transgene Expression immunmodulatorischer Moleküle auf leukämischen Lymphoblasten nach Transduktion mit Helfervirus - freien HSV-1 Amplikonvektoren

  2007cites this paper
• The Neurology of Neuroblastoma

  2002cites this paper
• Suicide gene therapy for pediatric tumors

  2001cites this paper